Nov 30, 2023 / 02:30PM GMT
Yasmeen Rahimi - Piper Sandler - Senior Research Analyst
Good morning, everyone. Thank you for joining our third day of Piper Healthcare Conference. Really excited to be featuring the team from Lexicon Pharmaceuticals with lots to cover over the next 25 minutes. First of all, congratulations on today's update on progress, enrollment, and start. And we'll talk about that, but just want to acknowledge just the really great news as we kicked off.
Questions and Answers:
Yasmeen Rahimi - Piper Sandler - Senior Research AnalystWe'll start first sort of on INPEFA launch because a lot of our investors are paying close attention. And then we'll go to today's update.
I guess the question that a lot of investors have is at this junction, the year's ending, INPEFA got approved with a phenomenal label. You've done a great job winning formula, and you're continuing to do that, and we'll talk about that into 2024. How do you -- why on now? Why at 2024 a very big inflection point for INPEFA that they need to not miss that in be owning ahead? And how do you
Trustpilot
